Loading...
NASDAQ: SNDX
Syndax Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market Cap
$2.09B
52w High
$25.16
52w Low
$8.58
P/E
-7.19
Volume
436.92K
Outstanding Shares
88.20M
Company profile
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.
CEOMichael A. Metzger
SectorHealthcare
IndustryBiotechnology
Employees270
IPO dateMar 2, 2016
Valuation
Forward P/E—
EV/EBITDA-8.07
Enterprise value$2.03B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth791.68%
Gross margin95.96%▼0.58%vs FY2024
Operating margin-158.45%▲88.95%vs FY2024
ROE-441.62%▼299.18%vs FY2024
Analyst consensus
RatingBuy
Target price$39.33▲65.95%
20
Buy
2
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 11, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
-$0.83
-$1.00
Q3FY25
ActualEst.
-$0.70
-$0.74
Q4FY25
ActualEst.
-$0.78
-$0.64
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$37.96M
$45.65M
Q3FY25
ActualEst.
$45.87M
$63.34M
Q4FY25
ActualEst.
$68.48M
$64.75M
Q1FY26
Next Est.
—